Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
Clinical trial NCT02525939 · COMPLETED
Trial details
- NCT number
- NCT02525939
- Sponsor
- DalCor Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-04-01
- Primary completion
- 2021-10-01
- Enrollment
- 6147
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.